- Home
- OVID vs SLGL Comparison
OVID vs SLGL Comparison
Compare OVID & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | SLGL |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 117.8M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OVID | SLGL |
|---|---|---|
| Price | $1.67 | $42.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $3.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.5M | 20.5K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,610,000.00 | ★ $18,970,000.00 |
| Revenue This Year | $1,077.56 | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 945.89 | 62.04 |
| 52 Week Low | $0.24 | $4.02 |
| 52 Week High | $2.01 | $52.26 |
Technical Indicators
Market Signals| Indicator | OVID | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 54.06 |
| Support Level | $1.59 | $40.10 |
| Resistance Level | $1.88 | $44.99 |
| Average True Range (ATR) | 0.12 | 2.97 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 66.13 | 62.41 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.